Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), today announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference, taking place June 15-16, 2026, will feature the fireside chat available on demand beginning June 15 at 7:00 a.m. EDT.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to addressing the large unmet need for people suffering from depression, anxiety, and other mental health conditions. The company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. With class-leading data, Helus Pharma aims to improve the treatment landscape by introducing NSAs that provide durable improvements in mental health.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma also has an extensive research portfolio of investigational NSAs.
The participation of Chief Medical Officer Amir Inamdar at the H.C. Wainwright conference underscores the company's commitment to advancing its pipeline and engaging with the investment community. The fireside chat is expected to cover the company's clinical programs, scientific approach, and future milestones.
For more information about Helus Pharma and its developments, visit the company's website at www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
This announcement is significant as it provides an opportunity for investors and analysts to gain insights into Helus Pharma's strategic direction and clinical progress. The company's novel approach to treating mental health conditions through NSAs could potentially transform the treatment landscape for millions of patients.
